Log in

Allogene Therapeutics Stock Forecast, Price & News

-1.65 (-4.64 %)
(As of 10/30/2020 12:00 AM ET)
Today's Range
Now: $33.92
50-Day Range
MA: $37.26
52-Week Range
Now: $33.92
Volume535,692 shs
Average Volume805,733 shs
Market Capitalization$4.72 billion
P/E RatioN/A
Dividend YieldN/A
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. It is also developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. Allogene Therapeutics, Inc. also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of AlloCAR T candidates across a portfolio of hematologic and solid tumors. The company was founded in 2017 and is headquartered in South San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:ALLO



Sales & Book Value

Annual SalesN/A
Book Value$5.16 per share


Net Income$-184,590,000.00


Market Cap$4.72 billion
Next Earnings Date11/4/2020 (Confirmed)
OptionableNot Optionable
-1.65 (-4.64 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALLO News and Ratings via Email

Sign-up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Allogene Therapeutics (NASDAQ:ALLO) Frequently Asked Questions

How has Allogene Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Allogene Therapeutics' stock was trading at $25.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ALLO shares have increased by 35.4% and is now trading at $33.92.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Allogene Therapeutics?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last year. There are currently 5 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Allogene Therapeutics

When is Allogene Therapeutics' next earnings date?

Allogene Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Allogene Therapeutics

How can I listen to Allogene Therapeutics' earnings call?

Allogene Therapeutics will be holding an earnings conference call on Wednesday, November 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Allogene Therapeutics' earnings last quarter?

Allogene Therapeutics, Inc. (NASDAQ:ALLO) announced its earnings results on Wednesday, August, 5th. The company reported ($0.53) earnings per share for the quarter, topping analysts' consensus estimates of ($0.54) by $0.01.
View Allogene Therapeutics' earnings history

What price target have analysts set for ALLO?

17 brokers have issued 12 month price targets for Allogene Therapeutics' stock. Their forecasts range from $27.00 to $70.00. On average, they anticipate Allogene Therapeutics' share price to reach $48.46 in the next twelve months. This suggests a possible upside of 42.9% from the stock's current price.
View analysts' price targets for Allogene Therapeutics

Who are some of Allogene Therapeutics' key competitors?

What other stocks do shareholders of Allogene Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and Crispr Therapeutics (CRSP).

Who are Allogene Therapeutics' key executives?

Allogene Therapeutics' management team includes the following people:
  • Dr. Arie S. Belldegrun F.A.C.S., M.D., FACS, Co-Founder & Exec. Chairman (Age 71, Pay $664k)
  • Dr. David D. Chang M.D., Ph.D., Co-Founder, Pres, CEO & Director (Age 60, Pay $1.21M)
  • Mr. Joshua A. Kazam, Co-Founder & Director (Age 43, Pay $603.9k)
  • Dr. Eric Thomas Schmidt Ph.D., Chief Financial Officer (Age 51, Pay $612k)
  • Dr. Alison Moore Ph.D., Chief Technical Officer (Age 53, Pay $612k)
  • Dr. Rafael G. Amado, Chief Medical Officer and Exec. VP of R&D (Age 56, Pay $442.56k)
  • Ms. Barbra Sasu, Chief Scientific Officer
  • Mr. Veer Bhavnagri, Gen. Counsel & Compliance Officer (Age 37)
  • Ms. Christine Cassiano, Chief Communications Officer
  • Dr. David M. Tillett, Sr. VP, Head of Quality

When did Allogene Therapeutics IPO?

(ALLO) raised $272 million in an IPO on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies served as the underwriters for the IPO.

What is Allogene Therapeutics' stock symbol?

Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO."

Who are Allogene Therapeutics' major shareholders?

Allogene Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include WINTON GROUP Ltd (0.06%), Candriam Luxembourg S.C.A. (0.05%), State of New Jersey Common Pension Fund D (0.05%), DekaBank Deutsche Girozentrale (0.03%), BNP Paribas Arbitrage SA (0.01%) and First Hawaiian Bank (0.01%). Company insiders that own Allogene Therapeutics stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Group Holdings (Sbs) Advis Tpg, Rafael Amado and Veer Bhavnagri.
View institutional ownership trends for Allogene Therapeutics

Which institutional investors are selling Allogene Therapeutics stock?

ALLO stock was sold by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, and Candriam Luxembourg S.C.A.. Company insiders that have sold Allogene Therapeutics company stock in the last year include Alison Moore, David D Chang, Eric Thomas Schmidt, Group Holdings (Sbs) Advis Tpg, Rafael Amado, and Veer Bhavnagri.
View insider buying and selling activity for Allogene Therapeutics

Which institutional investors are buying Allogene Therapeutics stock?

ALLO stock was bought by a variety of institutional investors in the last quarter, including DekaBank Deutsche Girozentrale, WINTON GROUP Ltd, State of New Jersey Common Pension Fund D, First Hawaiian Bank, Bourgeon Capital Management LLC, Aspiriant LLC, Pacer Advisors Inc., and Nisa Investment Advisors LLC.
View insider buying and selling activity for Allogene Therapeutics

How do I buy shares of Allogene Therapeutics?

Shares of ALLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Allogene Therapeutics' stock price today?

One share of ALLO stock can currently be purchased for approximately $33.92.

How big of a company is Allogene Therapeutics?

Allogene Therapeutics has a market capitalization of $4.72 billion. The company earns $-184,590,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. Allogene Therapeutics employs 236 workers across the globe.

What is Allogene Therapeutics' official website?

The official website for Allogene Therapeutics is www.allogene.com.

How can I contact Allogene Therapeutics?

Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-457-2700 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.